Evaluation of OPEN Zinc Finger Nucleases for Direct Gene Targeting of the ROSA26 Locus in Mouse Embryos

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1371/journal.pone.0041796</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:10528301">http://nrs.harvard.edu/urn-3:HUL.InstRepos:10528301</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Evaluation of OPEN Zinc Finger Nucleases for Direct Gene Targeting of the ROSA26 Locus in Mouse Embryos

Mario Hermann1,5, Morgan L. Maeder2, Kyle Rector3, Joseph Ruiz3, Burkhard Becher4, Kurt Bürki1, Cyd Khayter2, Adriano Aguzzi5, J. Keith Joung2,6, Thorsten Buch4,7,*, Pawel Pelczar1,9

1 Institute of Laboratory Animal Science, University of Zurich, Zurich, Switzerland, 2 Molecular Pathology Unit, Center for Cancer Research, and Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America, 3 Transposagen Biopharmaceuticals, Inc., Lexington, Kentucky, United States of America, 4 Institute for Experimental Immunology, University of Zurich, Zurich, Switzerland, 5 Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland, 6 Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America, 7 Institute for Medical Microbiology, Immunology, and Hygiene, Technische Universität München, Munich, Germany

Abstract

Zinc finger nucleases (ZFNs) enable precise genome modification in a variety of organisms and cell types. Commercial ZFNs were reported to enhance gene targeting directly in mouse zygotes, whereas similar approaches using publicly available resources have not yet been described. Here we report precise targeted mutagenesis of the mouse genome using Oligomerized Pool Engineering (OPEN) ZFNs. OPEN ZFN can be constructed using publicly available resources and therefore provide an alternative approach for academic researchers. Two ZFN pairs specific to the mouse genomic locus gt(ROSA26)Sor were generated by OPEN selections and used for gene disruption and homology-mediated gene replacement in single cell mouse embryos. One specific ZFN pair facilitated non-homologous end joining (NHEJ)-mediated gene disruption when expressed in mouse zygotes. We also observed a single homologous recombination (HR)-driven gene replacement event when this ZFN pair was co-injected with a targeting vector. Our experiments demonstrate the feasibility of achieving both gene ablation through NHEJ and gene replacement by HR by using the OPEN ZFN technology directly in mouse zygotes.

Introduction

Mouse lines carrying genes that have been disrupted (knocked-out) or modified (knocked-in) by homologous recombination (HR) are important tools that are widely used in biomedical research. Such lines are generated by gene targeting in mouse embryonic stem (ES) cells and subsequent morula aggregation or blastocyst injection of positive clones to generate chimeric animals [1,2]. Despite several improvements aimed at shortening the time frame of this approach [3] and considerable efforts of consortia such as EUCOMM, KOMP, or NorCOMM to target all mouse genes [4,5] engineering the mouse genome remains expensive, time-consuming and is often plagued by technical problems such as genomic stability of ES cells and subsequent difficulties in obtaining germline competent chimeras.

Zinc finger nucleases (ZFNs) have been conceived as an alternative means of selectively altering the eukaryotic genome [6]. ZFNs are custom endonucleases that generate double-strand breaks (DSBs) in their target DNA sequence. Each monomer consists of 3 to 6 DNA-binding zinc finger modules and the endonuclease domain of FokI [7]. The zinc finger modules specify a binding site of 9 to 18 bps thus allowing the design of ZFN pairs specific for “half-sites” with a total potential specificity of up to 36 bp in length. ZFN pairs can be produced by modular assembly of one-finger [8,9] or two-finger modules [10,11] with predefined binding characteristics or by selection-based methods such as the Oligomerized Pool Engineering (OPEN) protocol developed by the Zinc Finger Consortium (http://www.zincfingers.org) [12,13]. OPEN relies on a bacterial two-hybrid selection system [12] to identify ZFNs from combinatorial zinc finger libraries, which exhibit high activities and specificities for their intended target sites. OPEN ZFNs have been used to efficiently modify endogenous genes in zebrafish [14], plants [15,16], and human somatic [12] and pluripotent stem cells [17,18]. Using the sequences of a large number of OPEN ZFNs, a selection-free approach known as Context-Dependent Assembly (CoDA) was also recently described that yielded active ZFNs in zebrafish and plants with a success rate of approximately 50% [19,20].

DSBs caused by ZFN activity can be repaired by either error-prone non-homologous end joining (NHEJ), the dominating DNA repair mechanism in most eukaryotes [21], or by high fidelity HR [22]. ZFN-induced mutations caused by mutagenic NHEJ have...
been used to generate knockout zebrafish through microinjection of ZFN mRNAs or ZFN expression constructs directly into embryos [11,14,23] and similar approaches were also used to manipulate the genomes of rat [24–26] and mouse [27] following microinjection of zygotes. In a further refinement, HR-mediated gene targeting was achieved by co-injection of ZFN mRNAs together with targeting constructs into mouse and rat zygotes [28,29]. Most of these experiments were carried out with ZFNs generated by proprietary technology of Sigma-Aldrich/Sangamo BioSciences Inc.. By contrast, ZFNs generated using the OPEN platform and other publicly available assembly kits [30,31] can be constructed directly by the end user.

Here, we tested two OPEN ZFNs designed to target the mouse gt(ROSA26)Sor (ROSA26) locus. Our findings demonstrate that OPEN ZFNs can be used to achieve gene ablation through NHEJ and gene targeting by HR directly in mouse zygotes.

Results

The mouse ROSA26 locus is a “safe harbour” frequently used for site-specific insertion of transgenes by HR. Previous studies have demonstrated the feasibility of gene targeting in the ROSA26 locus by use of commercially available ZFNs [28]. In a complementary approach we wanted to investigate whether OPEN ZFNs also allow modification of the ROSA26 locus. Due to constraints in the targeting range of the OPEN system it was, however, not possible to target a ZFN pair directly to the XbaI site in the ROSA26 locus that is frequently used to insert transgenes. Instead, two ZFN pairs were used in our experiments that could mediate DNA cuts in proximity of this XbaI site. These ZFN pairs, 90/91 and 204/205, target the ROSA26 sequence 75 and 403 bp upstream of the XbaI site, respectively (Figure 1A, Table S1).

Initially, we injected ZFN pairs as in vitro synthesised mRNA into the cytoplasm of zygotes. Specific ZFN activity was estimated by the number of imprecise NHEJ events in the genome of the resulting offspring. Cytoplasmic microinjection of mRNAs encoding the 90/91 heterodimeric pair did not result in any discernable ZFN activity either in the form of mutagenic NHEJ or through HR upon co-injecting the pRosa26.8 donor construct [28] (Table 1) that induces alterations at the XbaI site 75 bp downstream of the 90/91 cleavage site. Also cytoplasmic microinjection of mRNAs encoding the 204/205 homodimeric ZFN pair at a concentration of 10 ng/μl appeared to be toxic and did not result in genome modification through NHEJ. In addition, we observed high toxicity but no NHEJ or HR after co-injections of the same mRNAs with targeting vector grR26_EGFP containing an EGFP expression cassette sized 3.5 kb and equipped with 1.4 and 1.8 kb long homology arms flanking the ZFN recognition site (data not shown). This toxicity also persisted upon co-injection of 1.4 and 1.8 kb long homology arms flanking the ZFN recognition site, contained identical 23 bp deletions (Figure 1A,B, Figure S1B).

To investigate the possibility of using the 204/205 ZFN pair to induce HR at the ZFN cleavage site, we co-injected the ZFN mRNAs with a linear DNA fragment of the targeting vector grR26_EGFP. We identified 16 fluorescent founder animals and could confirm that one of them carried the grR26_EGFP cassette correctly integrated into the ZFN target site as confirmed by Southern blot analysis (Figure 2B) as well as by junction PCR and sequencing (Figure 2B, S2). The integrated EGFP transgene could be passed to the next generation and remained active in F1 offspring (Figure 2C,D). In further experiments we co-injected the full-length super-coiled grR26_EGFP targeting vector, since vectors with super-coiled topology served as efficient donors in previous studies [28,29]. We failed, however, to observe HR in this particular experiment (Table 1).

To test whether integration at the ZFN 204/205 cleavage site would allow transgene expression under the same transcriptional control as has been reported before for ROSA26 insertion transgenes, we co-injected the linear targeting construct grR26_tdT carrying a 2.5 kb splice-acceptor tdTomato cassette. Despite identifying 12 pups that expressed tdTomato and several others carrying independent NHEJ events, we could not identify any animals with homologous integration of the grR26_tdT vector as determined by Southern blot and junction PCR even though NHEJ events were present (Table 1, data not shown). This result shows that despite ZFN activity, the grR26_tdT expression cassette did not integrate into the ROSA26 locus. This observation was surprising because the grR26_tdT vector included identical homology arms and a smaller insert compared to grR26_EGFP. Therefore, we conclude that the 12 tdTomato expressing mice are most likely the result of random transgene integration and a partially active ROSA26 promoter that was included in the left homology arm of the grR26_tdT construct.

Discussion

Nuclease-assisted gene targeting in zygotes offers a more expeditious alternative when compared to standard gene targeting in mouse ES cells. This becomes particularly important for frequently targeted loci such as ROSA26. An additional advantage comes with the species and strain-independent cleavage mechanism of ZFNs, which allows generation of germline-competent founders in all organisms accessible to embryo manipulation [32]. We explored the potential of OPEN ZFNs as an alternative for targeted transgenesis in mouse embryos and conclude that OPEN ZFN mRNAs can be used to engineer the mouse genome by direct zygote injection.

Injection statistics compiled in Table 1 clearly show that in the case of zygotes expressing the ROSA26 ZFN 204/205 heterodimer pair NHEJ repair occurs more frequently than HR as described in earlier studies [28,29]. NHEJ events observed in 4 to 9% of offspring with this single pair are well within the range of NHEJ frequencies observed in other studies using ZFNs from OPEN selection or the CoDA pool in human cells, zebrafish embryos or plants [12,15,19]. However, in rodent zygotes NHEJ modification rates above 20% were reported after microinjection of ZFNs obtained through the Sigma-Aldrich CompoZr service [27–29]. Mosaicism and the presence of two or more modified alleles in a single animal were frequently observed in these studies. We identified one founder, ZGP1P12, carrying an identical deletion in both ROSA26 alleles. This genotype could be the result of a primary NHEJ deletion in one allele which served as a homologous donor in the subsequent repair of the second DSB

OPEN ZFNs for Gene Targeting in the Mouse Embryo
by HR. Alternatively, microhomology domains (Figure S1B) in proximity to a DSB could have triggered a preferential mode of end-joining leading to identical outcomes of individual repair events [27]. Whether the lower ZFN activity rates in our study as compared to previous studies are the result of locus-dependent effects, differences in ZFN binding activity, variations in injection procedures, or lack of codon optimization in our ZFN expression vectors for expression in mammalian cells will only be revealed by further comparative studies. Also, a recent study showed that, at least in cultured cells, the cleavage activity of ROSA26-specific ZFNs generated by modular assembly [33] increased significantly upon incorporation of additional ZF modules. However, we note that this strategy does not always increase activity and care must be taken with the choice of linkers used to add more fingers because these more extended ZFNs can potentially bind to a greater range of off-target sites using subsets of fingers [10].

Meyer and colleagues reported successful vector integration into ROSA26 in 1.7% to 4.5% of pups born. In our study, HR-mediated modification of the ROSA26 was observed in a single germline-competent founder out of 51 mice born after co-injecting 585 zygotes with ZFN 204/205 mRNA and the linear gtR26_EGFP donor construct. Surprisingly, no targeted integration was detected when supercoiled gtR26_EGFP, the preferred donor topology used in earlier studies [28,29], or linear gtR26_tdT, a targeting vector with identical homology arms, were co-injected with ZFNs 204/205. Thus, a total of 1500 zygotes were injected with ZFNs 204/205 together with donor constructs to yield a single targeted founder. While we cannot formally exclude that the observed targeted integration event results from the resolution of a spontaneously occurring DSB and is unrelated to ZFN activity, this scenario seems rather unlikely in light of previously published data. To date, only one study has ever

![Figure 1. Non-homologous end joining repair of ZFN-generated double-strand breaks within the ROSA26 locus.](A) Schematic of ZFN 90/91 and 204/205 target sites within ROSA26 intron 1. ZFN pairs 90/91 and 204/205 target sites 75 bp and 403 bp upstream of the XbaI site (white arrows), which is routinely used in ROSA26 targeting, respectively. ZFNs 204/205 target a partial FspI recognition sequence. RF and RR, ROSA26 forward and reverse primers used for NHEJ analysis generating a 474 bp fragment (black arrows). (B) Screening for NHEJ repair at the ZFN204/205 cleavage site. Genomic DNA extracted from fetuses or pups developing from ZFN-injected zygotes was amplified with primers RF and RR and subjected to FspI restriction digest. Most error-prone NHEJ repair events eliminate the FspI recognition sequence (underlined in C) resulting in an indigestible band at 474 bp. In the majority of founders such as Z20 both modified and wt alleles were detected, however only mutated alleles were present in founder ZGFP112. (C) Cloning and sequencing of undigested PCR products reveals mutations around the ZFN204/205 cleavage site. Founder ZGFP112 carried an identical 23 deletion in both ROSA26 alleles. ZFN 204/205 recognition sites highlighted in bold and the spacer region in grey color.

doi:10.1371/journal.pone.0041796.g001
Table 1. Compilation of zygote microinjection experiments.

<table>
<thead>
<tr>
<th>ZFN Pair Vectors</th>
<th>Cargo Conc. ng/ml</th>
<th>Substrate Conc. ng/ml</th>
<th>Mutated (% of transferred)</th>
<th>Phenotype</th>
<th>Zygotes injected/transfered</th>
<th>Born (% of transferred)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MLM290/292 heterodimers</td>
<td>mRNA 10</td>
<td>TV 10</td>
<td>8/10</td>
<td>27/12</td>
<td>90/91</td>
<td>30 (8.7)</td>
</tr>
<tr>
<td>pST1374 homodimers</td>
<td>mRNA 10</td>
<td>TV 10</td>
<td>4/8</td>
<td>51/17</td>
<td>204/205</td>
<td>4 (0.1)</td>
</tr>
<tr>
<td>pST1374 homodimers</td>
<td>mRNA 2</td>
<td>TV 2</td>
<td>1</td>
<td>124/36</td>
<td>87/303</td>
<td>51 (7.2)</td>
</tr>
<tr>
<td>MLM290/292 heterodimers</td>
<td>mRNA 10</td>
<td>TV 10</td>
<td>51/17</td>
<td>358/192</td>
<td>204/205</td>
<td>27 (14.1)</td>
</tr>
<tr>
<td>pST1374 homodimers</td>
<td>mRNA 2</td>
<td>TV 2</td>
<td>10</td>
<td>585/256</td>
<td>204/205</td>
<td>4 (2.36; E)</td>
</tr>
<tr>
<td>MLM290/292 heterodimers</td>
<td>mRNA 10</td>
<td>TV 10</td>
<td>5</td>
<td>640/287</td>
<td>4523/2404</td>
<td>87 (30.3; E)</td>
</tr>
</tbody>
</table>


* pRosa26.8 described in [28].

ZFNs compare in general with other systems in supporting HR in mouse zygotes. Since we observed only one out of the two OPEN ZFN pairs showed both NHEJ and HR activities in mouse zygotes. Recently described novel reporter systems translating nuclease-induced frameshift events into a switch between two discrete fluorescent signals [36,37] may be useful to quickly identify active ZFNs in cultured cells prior to commencing the actual gene targeting experiments in zygotes. In addition to ZFNs, the recently described TAL Effector Nucleases (TALENs) show promise as an alternative method for rapid assembly of site-specific nucleases [38–42], but have to still prove their potential for use in mouse oocytes.

Based on the experiments presented here, OPEN ZFNs represent viable tools for achieving NHEJ-mediated gene knockout in mouse zygotes. Since we observed only one event, we cannot estimate the efficiency of OPEN ZFN heterodimers for achieving integration of a targeting vector into the ROSA26 locus. Only further experiments will reveal how OPEN ZFNs compare in general with other systems in supporting HR in mouse zygotes.

**Materials and Methods**

**Animals**

Females and males of BDF1 (B57BL/6×DBA/2), C57BL/6, and CD1 mice were purchased from a commercial breeder (Charles River, Germany). All animals were maintained in temperature- and light-controlled rooms (12 light/12 dark, light on from 6:00 a.m.) with food and water ad libitum. All experiments including laboratory animals were approved by the Cantonal Veterinary Office of Zurich. The protocol of animal handling and treatment was in accordance with Swiss Federal and Cantonal regulations as well as the internal guidelines of the University of Zurich.

**Embryo Collection, Culture and Manipulation**

B6D2F1 or C57BL/6 female mice underwent ovulation induction by intra peritoneal (i.p.) injection of 5 IU pregnant mare’s serum gonadotrophin (PMSG; Folligon – InterVet, Switzerland), followed by i.p. injection of 5 IU human chorionic gonadotropin (hCG; Pregnyl – Essex Chemie, Switzerland) 48 h reported spontaneous homologous integration of a targeting construct into the genome of microinjected zygotes and more than 10,000 zygotes were injected to obtain a single targeting event in that report [34].

The issue of ZFN toxicity has often been raised as an indicator for off-target ZFN activity and thus a potential limitation of the technology. Although the mice generated in this study were not tested for off-target cleavage events, we have not observed a marked increase in embryo lethality upon injection of any heterodimeric ZFNs as compared to conventional pronuclear injections routinely performed in our laboratory. This is in stark contrast to microinjections of homodimeric ZFNs, which caused significant embryo lethality most likely due to more frequent off-target cleavage events [35].

Thus far, the influence of ZFN activity on gene targeting efficiency has not been studied comprehensively in microinjected embryos. However, earlier studies [28,29] suggest a positive correlation between the number of NHEJ repair events and HR-mediated targeting events, which both depend on the frequency of DSBs and ultimately on ZFN activity. The size of the desired modification is clearly another factor influencing targeting efficiency with small modifications such as adding or replacing a small number of nucleotides clearly faring better than experiments requiring integration of large inserts at the same locus [29].
later. For the recovery of zygotes, the B6D2F1 and C57BL/6 females were mated with the males of the same strain immediately after the administration of hCG. All zygotes were collected from oviducts 24 h after the hCG injection and were then freed from any remaining cumulus cells by a 1–2 min treatment of 0.1% hyaluronidase (Sigma) dissolved in M2 medium.

Mouse embryos were cultured in M16 (Sigma) medium at 37°C and 5% CO2. For micromanipulation the embryos were transferred into M2 medium (Sigma).

**Cytoplasmic and pronuclear microinjections**

All microinjections were performed using a microinjection system comprised of an inverted microscope equipped with Nomarski optics (Nikon, Japan), set of micromanipulators (Narashige, Japan) and a FemtoJet microinjection unit (Eppendorf, Germany). ZFN mRNAs were injected into the cytoplasm whereas the DNA expression constructs and DNA targeting fragments were injected into the male pronuclei; in experiments where mRNA and DNA were co-injected the RNA DNA mixture was first injected into the male pronucleus and subsequently into the cytoplasm upon the withdrawal of the microinjection capillary. Specific concentrations of injected mRNAs and DNA constructs are compiled in Table 1.

**Embryo Transfer**

Embryos that survived the microinjection were transferred on the same day into the oviducts of 8–16 weeks old pseudopregnant CD-1 females (0.5 days post coitus) that have been mated with sterile TgV males [43] on the day before embryo transfer. Pregnant females were allowed to deliver and raise their pups or were sacrificed at 14–16 days post embryo transfer so that the developing foetuses could be removed for analysis.

**Construction of ZFN expression vectors and mRNA preparation**

Zinc finger proteins binding target sites 75 and 403 bp upstream of the XhoI site within the ROSA26 intron 1 were selected using the previously described OPEN method [12]. Selected zinc fingers (Text S1) were cloned as XhoI-BamHI fragment into either the expression vectors pST1374 or pMLM290/pMLM292 that express homo- or heterodimeric ZFNs, respectively [35]. In both ZFN expression vectors, the CMV promoter was replaced by a CMV early enhancer element/chicken beta-actin promoter (CAG) promoter [44].

In vitro mRNA transcription, capping and polyadenylation, was performed using the mMESSAGE mMACHINE T7 Ultra Kit. Prior to injection the mRNAs were purified using the NucAway
Construction of targeting vectors

Targeting vector GTR26 includes a 1.4 kb 5’ ROSA26 homology arm and a 1.8 kb 3’ ROSA26 homology arm flanking a central ScaI restriction site. An expression cassette consisting of a 1.6 kb CAG promoter/enhancer followed by the 720 bp EGFP coding region and the 531 bp rabbit beta-globin polyadenylation site (3.5 kb in total, including 5’ and 3’ flanking sequences) was inserted by blunt cloning into the ScaI site to generate targeting vector GTR26-EGFP. To generate targeting vector GTR26-tdT a cassette including the 104 bp Ad2 splice-acceptor followed by a 500 bp triple-STOP-pCMV-IREs fragment, the 1.4 kb tdTomato coding region and the 256 bp TK polyadenylation signal (2.5 kb in total, including 5’ and 3’ flanking sequences) was PCR-amplified from pXLBluescriptII PTS tdTomato (gift of J. Ruiz and K. Rector) using primers AGG GCC CAG TAG FCC AGG GTT TCC and GCC TAT GCC AGG GCT TGC TGC CGC C with Pfu polymerase and cloned into the ScaI site of the GTR26 targeting vector. To generate a linear fragment all GTR26-based targeting vectors were PspI digestion prior to microinjection.

NHEJ and Targeted integration detection assays

Genomic DNA was extracted from mouse biopsies or fetal tissue using a buffer containing 10 mM Tris-HCl pH 9, 50 mM KCl, 0.45% Nonidet p40, 0.45% Tween 20 and Proteinase K. Extracts were subjected to Phenol/Chloroform/Isoamyl alcohol purification, precipitated with Isopropanol, and dissolved in EB buffer (Qiagen).

For detecting NHEJ repair at the ROSA26 locus, primers RF (GCC GCC CAC CCT CTT CTT CCT) and RR (CCG CTA CT CCA CTG CAG CTC CC) were used to amplify a 474 bp fragment surrounding the ZFN204/205 target site. 25 μl of each PCR product were digested with Pfu and subsequently resolved on a 2% agarose gel. Samples including undigested PCR fragments were cloned into pGEM-T easy (Promega) for Sanger sequencing.

Targeted integration of donor vectors was assessed by junction PCR and Southern blotting. In case of ZFN204/205-mediating ROsa26 targeting primers GF (GCC GCC CAC CCT CTT CTT CCT) and GR (CCG CTA CT CCA CTG CAG CTC CC) were used to amplify a 474 bp fragment surrounding the ZFN204/205 target site. 25 μl of each PCR product were digested with Pfu and subsequently resolved on a 2% agarose gel. Samples including undigested PCR fragments were cloned into pGEM-T easy (Promega) for Sanger sequencing.

Acknowledgments

The authors thank Sabine Speth for assistance with Southern blot analysis, Patrick Stillhard for assistance in screening mice originating from ZFN microinjections, and Monika Tarnowska, Ewa Skoczyńska, and Cornelia Albrecht for excellent technical assistance.

Author Contributions

Conceived and designed the experiments: TB PP JKJ. Performed the experiments: MH TB PP MLM KR JR. Analyzed the data: MH TB PP. Contributed reagents/materials/analysis tools: AA BB KB KR JR CK. Performed the experiments: TB PP JKJ. Wrote the paper: PP MH. Supervision of Experiments: TB PP AA BB KB [JK].

References


Table S1 Sequences of ZFN target sites.

Figure S1 Sequencing of ZFN204/205 cleavage site within ROsa26 locus. (A) Sequencing traces for NHEJ-modified ROsa26 alleles. One representative trace per founder is shown. (B) NHEJ-modified alleles in founder ZGFP112. A deletion of 23 bp around the ZFN204/205 cleavage site could be identified in both ROsa26 alleles in founder ZGFP112. The presence of a C/T SNP (red arrow) 33 bp upstream of the ZFN cleavage site (underlined in red) in this founder enabled the identification of individual ROsa26 alleles. Possible regions of microhomology, which can attract NHEJ repair and increase the likelihood of certain NHEJ repair outcomes are underlined in black.

Text S1 Sequences of OPEN Zinc Finger modules used in this study.

Supporting Information

Figure S2 Sequencing of junction PCR product amplified from a founder carrying a targeted ROsa26 allele.

The upper panel shows the parts being sequenced with (1) covering parts of the EGFP open reading frame and the polyadenylation signal and (2) covering the junction of ROsa26 genomic DNA and the 3′ homology arm of integrated targeting construct GTR26_EGFP.


